The point was never the variant
The point was never the variant
There is a particular kind of question that follows a case report like ours around the room. A colleague reads it, nods and then says some version of, “The gene is known, the variant is already in the literature, the phenotype is more or less textbook - so what, exactly, is new here?”
It is a fair question. And the honest answer is that, in the way genomics usually keeps score, almost nothing is new. We did not discover a gene. We did not describe a variant the world had never seen. Judged purely on novelty, this paper has very little to offer.
A different kind of contribution
Genomics has trained us to reward the new - a new gene, a new mechanism, a new variant prised out of a difficult region of the genome. It is a good instinct and it has built the field. But it is not the only thing worth publishing and in our setting, new and novel may not even be the most important thing.
What this case report puts on the record is not a discovery about the genome. It is a demonstration about a country. Every step - from a South African research participant, through sequencing, through analysis and interpretation, to a confirmed answer - was done here, by people working here, on infrastructure here. The variant was old news. The chain of custody was the story.
This distinction matters more than it sounds, because the history of African genomics is full of samples that left the continent to be sequenced somewhere else, analysed by someone else and written up as someone else's contribution.
"Helicopter research" is the polite name for it.
A case report that is unremarkable on the variant and entirely local on the provenance is a quiet refusal of that pattern. It says: the whole loop can close inside South Africa. We have now shown, on the record and in the open literature, that it does.
Research first, medicine second - and that order is deliberate
It is worth being precise about what this is. This is genomic research: researchers and a consenting research participant, governed as research, reported as research.
It is not yet genomic medicine, which is a different thing - clinicians and patients, inside a health system, with all the assurance and accountability that clinical care demands.
We sometimes talk as though we could leap straight to the second. We cannot, and we should not want to.
Genomic medicine for rare disease is not something a country switches on; it is something a country earns, by accumulating local evidence that the methods work, that the pipelines are sound, that the answers hold up, that the costs are bearable, that the whole apparatus behaves the way it does in the papers - here, on our genomes, in our hands.
It is important to admit that a single case report does not build that system. It lays one brick. But you cannot point at the absence of a wall as a reason not to lay bricks. This is how the evidence base for a clinical service gets built: deliberately, locally, one defensible result at a time. Publishing it - rather than letting it sit in a freezer or a folder - is what turns a private capability into shared evidence other people can cite, challenge and build on.
Why we are doing this at all
The vision underneath the work is simple to state and hard to honour: a South Africa in which even a person with a rare disease can be offered a real answer. Not an answer outsourced abroad. Not an answer that depends on which referral managed to reach a foreign lab. An answer generated within the country's own system, for its own people.
If that is the destination, then the road to it is paved with exactly this sort of evidence - local, incremental, unglamorous, peer-reviewed. Each result that demonstrates the chain working end-to-end makes the next funding case, the next accreditation conversation, the next clinical pilot a little less speculative and a little more grounded.
The case for going long-read first
There is one more argument this case lets us make, and it is the one most likely to be useful to people deciding where to spend scarce money.
In well-resourced systems, long-read sequencing tends to be treated as a last resort - the test you reach for after short-read exome or genome sequencing has already failed, after the diagnostic odyssey has dragged on for years. That ordering is an accident of how those systems grew up, not a law of nature.
For a setting like ours, the path can be different. A single long-read assay can, in one workflow, capture small variants, structural variants, repeat expansions, methylation signal and the phasing that tells you which variant sits on which chromosome - the very classes of variation that short reads miss and that then trigger expensive, sequential reflex testing. Where you cannot afford a years-long cascade of tests, the appeal of one comprehensive test up front is obvious. It is the same logic that let much of Africa skip landlines and go straight to mobile: when you are building rather than retrofitting, you are free to adopt the better technology first rather than last.
We are not claiming this case settles that question. We are claiming it adds a real, local data point to an argument that South Africa should be having on its own terms - and arguing, on the strength of it, that long-read sequencing deserves serious consideration as a first-tier diagnostic test for rare disease here, not a consolation prize at the end of the road.
So, why publish it?
Because the least novel paper we could write was, for our context, one of the most necessary. The variant was never the point. The point was to prove - openly, locally and on the record - that the work can be done here, by us, for the people who need it; and to lay down a brick in the evidence base that a South African genomic medicine service for rare disease will one day have to stand on.
When that service exists, and a patient with something almost no one else has finally gets an answer at home, this will have been one of the small, deliberate, unglamorous results that made it possible.